Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Purple Biotech ( (PPBT) ).
On March 28, 2025, Purple Biotech announced that three of its posters have been accepted for presentation at the 2025 American Association for Cancer Research Meeting, scheduled for April 25-30 in Chicago. These presentations will cover the company’s advancements in cancer treatment, including CM24 for pancreatic cancer and NT219 for colorectal and head and neck cancers. This development highlights Purple Biotech’s ongoing efforts to enhance its position in the oncology market by showcasing its innovative therapies.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications. Purple Biotech is headquartered in Rehovot, Israel.
YTD Price Performance: -39.98%
Average Trading Volume: 34,463
Technical Sentiment Signal: Hold
Current Market Cap: $7.49M
See more data about PPBT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue